Skip to content

Safety evaluation of novel bath solution

Safety evaluation of novel bath solution in patients with atopic dermatitis and xerosis - Safety evaluation of novel bath solution in patients with atopic dermatitis and xerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000043385
Enrollment
40
Registered
2021-02-19
Start date
2021-02-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis, Xerosis and the like with mild to moderate dry skin symptoms

Interventions

Use of the test bath solution at least 5 times a week for 4 weeks

Sponsors

Medical Corporation Hokubukai Utsukushigaoka Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with mild to moderate dry skin symptoms(Atopic dermatitis,Xerosis and the like) 2. Patients with mild to moderate dry skin symptoms at the examination areas 3. Japanese men and women between the ages of 20 and 69 4. Patients giving written informed consent with his or her own will after receiving an adequate information about the test bath solution and aim of this study

Exclusion criteria

Exclusion criteria: 1. Patients with rashes at the examination areas that intervene the evaluation 2. Patients with rosacea-like dermatitis or with steroid skin disease 3. Patients who take or anticipate to take medicines that affect the study such as oral steroids, immunosuppresant 4. Patients who have applied medicine or moisturizing agent over the examination areas 5. Patients who have applied cosmetics or quasi-medicine that have moisturizing effect 6. Pregnant women 7. Lactating women 8. Patients who have experienced severe skin symptoms many times due to the use of cosmetics in the past 9. Patients who are judged as inappropriate by principal investigator or sub-investigator with other reasons

Design outcomes

Primary

MeasureTime frame
Skin findings(1) and adverse events(2) : dermatologist examination,questionnaire for skin condition and the impression of test bath solution,recording,daily life (1) 0 week,2 week,4 week (2) 2 week,4 week

Secondary

MeasureTime frame
Improvement of dryness and desquamation : dermatologist examination,photographic recording 0 week,2 week,4 week

Countries

Japan

Contacts

Public ContactTakuya Matsuda

Medical Corporation Hokubukai Utsukushigaoka Hospital Center for Clinical Pharmacology

matsuda@ughp-cpc.jp011-882-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026